Company will test its DNA methylation biomarkers on GSK samples.



OncoMethylome Sciences and GlaxoSmithKline Biologicals will collaborate to develop DNA methylation biomarkers for use in the personalization of cancer treatment with certain immunotherapeutics in development by GSK Biologicals.


“We look forward to using our high-throughput platform to efficiently test our portfolio of methylation biomarkers on clinical samples provided by GSK Biologicals,” commented Jim DiGuiseppi, CTO of OncoMethylome. 








This site uses Akismet to reduce spam. Learn how your comment data is processed.